IRIS
PANE, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.624
EU - Europa 3.207
AS - Asia 816
SA - Sud America 608
AF - Africa 86
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 9.345
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.365
IT - Italia 1.491
CN - Cina 653
BR - Brasile 420
UA - Ucraina 368
NL - Olanda 345
IE - Irlanda 288
FI - Finlandia 259
DE - Germania 169
MX - Messico 143
SE - Svezia 105
CA - Canada 101
VN - Vietnam 94
CI - Costa d'Avorio 86
GB - Regno Unito 67
CO - Colombia 54
EC - Ecuador 41
FR - Francia 33
ES - Italia 27
IN - India 26
PE - Perù 25
AR - Argentina 23
BO - Bolivia 21
CL - Cile 16
SG - Singapore 11
BG - Bulgaria 9
CH - Svizzera 9
HK - Hong Kong 9
IR - Iran 7
CZ - Repubblica Ceca 6
VE - Venezuela 6
JP - Giappone 5
CR - Costa Rica 4
HN - Honduras 4
PS - Palestinian Territory 4
PT - Portogallo 4
TR - Turchia 4
BE - Belgio 3
DO - Repubblica Dominicana 3
RO - Romania 3
RU - Federazione Russa 3
AU - Australia 2
EU - Europa 2
HR - Croazia 2
KR - Corea 2
NO - Norvegia 2
RS - Serbia 2
SI - Slovenia 2
SM - San Marino 2
UY - Uruguay 2
AT - Austria 1
DK - Danimarca 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
KN - Saint Kitts e Nevis 1
MK - Macedonia 1
PA - Panama 1
PL - Polonia 1
SV - El Salvador 1
VA - Santa Sede (Città del Vaticano) 1
Totale 9.345
Salva come PNG Salva come JPEG
Città #
Chandler 783
Jacksonville 351
Amsterdam 341
Millbury 311
Princeton 283
Napoli 239
Nanjing 204
Ashburn 198
Naples 198
Boston 160
Des Moines 150
Wilmington 136
Beijing 130
Dong Ket 94
Ottawa 87
Nanchang 69
Woodbridge 64
Lawrence 54
Hebei 51
Rome 45
Jiaxing 40
Seattle 40
Shenyang 38
Norwalk 37
Ann Arbor 34
Milan 32
Changsha 24
Dublin 24
Tianjin 24
Lima 22
Quito 22
Mexico 21
São Paulo 21
Kunming 20
Redwood City 20
Kronberg 19
Falls Church 18
Medellín 18
Houston 16
La Paz 16
Boardman 14
Nocera Inferiore 13
Pune 12
Santiago 12
Washington 12
Bogotá 11
Cuenca 10
Genova 10
Orange 10
Brasília 9
Caserta 9
Fairfield 9
Fortaleza 9
Salvador 9
Shanghai 8
Sofia 8
Campagna 7
Guidonia 7
Hangzhou 7
Marano 7
Marano di Napoli 7
Mountain View 7
Palermo 7
Salerno 7
Tijuana 7
Augusta 6
Bologna 6
Buenos Aires 6
Genoa 6
Hanover 6
Hong Kong 6
Los Angeles 6
Luzzano 6
Menlo Park 6
Monterrey 6
Osimo 6
Palmi 6
Veracruz 6
Verona 6
Bari 5
Belo Horizonte 5
Brescia 5
Duncan 5
Gesualdo 5
Lanzhou 5
Madrid 5
Marcianise 5
Mendoza 5
Parabiago 5
Paris 5
Rio De Janeiro 5
Santa Cruz 5
Siena 5
Singapore 5
Campo Grande 4
Catania 4
Cava 4
Federal 4
Feira De Santana 4
Frankfurt am Main 4
Totale 4.865
Salva come PNG Salva come JPEG
Nome #
Leucemia Mieloide Cronica 1.325
Frequenza delle mutazioni c-kit in pazienti affetti da Leucemia mieloide acuta (LAM) caratterizzata da alterazioni del gene del core binding factor (CBF) 268
Biochimica del pancreas 144
NANOG: ITS ROLE IN THE TKI RESISTANCE OBSERVED IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA 80
(1-3)-β-d-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations 80
Reduced regulatory T cells (Treg) in bone marrow preferentially associate with the expansion of cytotoxic T lymphocytes in low risk MDS patients. 74
Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient 72
Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry 67
2-deoxy-2[F-18] fluoro-D-GLUCOSE POSITRON EMISSION TOMOGRAPHY Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma 63
RISPOSTA EMATOLOGICA AL TRATTAMENTO CON LENALIDOMIDE IN UNA PAZIENTE AFFETTA DA TROMBOCITEMIA ESSENZIALE JAK2 V617F-POSITIVA E SINDROME MIELODISPLASTICA ASSOCIATA A DEL(5Q) 56
A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison 56
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. 55
Transition index: new original tool to identify subsets overlapping MPN phenotypes. 53
Eltrombopag for post-transplant cytopenias due to poor graft function 51
Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience 51
A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia 50
Secondary syphilis mimicking malignancy: A case report and review of literature 50
An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia 50
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 49
WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene 49
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL 49
Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+) and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+) lymphoma/leukemia. 47
Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma 47
Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: A real-life experience 46
Hashimoto Thyroiditis in Primary Thyroid Non-Hodgkin Lymphoma 46
Advanced-stage Hodgkin Lymphoma: US/Chest Radiography for Detection of Relapse in Patients in First Complete Remission—A Randomized Trial of Routine Surveillance Imaging Procedures 45
SPLEEN VOLUME IS THE MOST ACCURATE PARAMETER TO AVOID UNDERSTIMATION OF 25% SPLENOMEGALIC PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 45
Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1,3-β-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography 45
Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma 45
Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-),derived from a single patient with CD56+ non- Hodgkin's lymphoma. 44
Coesistence of two distinct cell populations (CD56+Tcr gammadelta+ and CD56+ Tcr gammadelta-) in a case of aggressive CD56+ lymphoma/leukemia 44
Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II 44
Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma 44
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. 42
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. 42
Clinical relevance of intrahepatic hepatitis B virus DNA in HBsAg-negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for hematological malignancies. 42
Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience 42
Excellent outcome of concomitant intensive immunosuppression and eculizumab in aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome. 42
Randomized comparison of power Doppler ultrasound-directed excisional biopsy with standard excisional biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma 41
Acute promyelocytic leukemia after treatment for non-Hodgkin lymphoma with drugs targeting topoisomerase II. 41
ALEMTUZUMAB FOR APLASTIC ANEMIA AND RELATED IMMUNE-MEDIATED BONE MARROW FAILURES: LONG-TERM FOLLOW UP OF A PILOT STUDY 41
[Complete diagnostic work-up provides the rational basis for the most appropriate therapy of myelodysplastic syndromes] 41
2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis 41
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis 41
Correspondence in reference to the previously published Epub manuscript by Peter Hokland et al. 'How I treat advanced Hodgkin lymphoma - a global view'. Br J Haematol. 2020;190:837-50 41
Coexistence of two distinct cell populations (CD56+TcRgd+ and CD56+TcRgd-) in a case of aggressive CD56+ lymphoma/leukemia 40
Estimation of bulky lymph nodes by power Doppler ultrasound scanning in patients with Hodgkin's lymphoma: a prospective study 40
Livelli sierici degli isoenzimi della LDH e della pseudoridina in leucemie e linfomi 40
Acquired Hb H disease associated with elevated Hb F level in patient affected by primary myelofibrosis. 40
Allo-SCT for myelofibrosis: Reversing the chronic phase in the JAK inhibitor era¿ 40
Myeloma and other monoclonal gammopathies - Clinical SINONASAL EXTRAMEDULLARY PLASMACYTOMA: PROPOSAL OF PROTOCOL OF FOLLOW-UP 40
Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies—bendamustine and G-CSF support 40
Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study 39
Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol 39
SAVING MONEY AND COMFORT BY GAINING CYTOSINE ARABINOSIDE MICROGRAMS 39
FLUORESCENT IN SITU HYBRIDIZATION (FISH) ON PERIPHERAL BLOOD AND BONE MARROW SMARS: 120 MINUTES FOR DETECTION OF PML/RARa FUSION GENE 39
MOLECULAR EVALUATION OF ZNF224 MRNA EXPRESSION IN CML PATIENTS AS A NOVEL DETERMINANT OF TKI RESPONSIVENESS 39
Longitudinal strain of left ventricular basal segments and E/e′ ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: An automated function imaging study 39
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia 38
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 38
Complete phenotypic and genotypic lineage switch in a Philadelphia chromosome-positive acute lymphoblastic leukemia. 38
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). 38
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 38
Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma 38
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. 37
Pseudouridine and 1-ribosylpyridin-4-one-3-carboxamide (PCNR) serum concentrations in human immunodeficiency virus type 1-infected patients are independent predictors for AIDS progression 37
Amyloid in bone marrow smears of patients affected by multiple myeloma. 36
Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia. 36
New insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: the role of Shp1 and Shp2 36
Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. 36
Fine needle aspiration cytology and flow cytometry immunophenotyping of non-Hodgkin lymphoma: can we do better?. 36
LONG-TERM FOLLOW UP OF ALENTUZUMAB-BASED IMMUNOSUPPRESSION FOR THE TREATMENT OF IMMUNE-MEDIATED BONE MARROW FAILURE SYNDROMES 36
PEGYLATED-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION: SINGLE CENTRE EXPERIENCE 36
18F-FDG-PET/CT, 99mTc-MIBI and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study 36
Acute immune toxicity during anti-thymocyte globulin: That's CARPA! 36
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical relation. 35
Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin's lymphoma. 35
Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. 35
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia 35
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. 34
Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon 34
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 34
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate 34
Additional chromosomal abnormalities in Ph positive clone: adverse prognostic influence on frontline imatinib therapy, a GIMEMA WP on CML analysis. 34
PEG-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION : A SINGLE-CENTRE EXPERIENCE 34
All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri 34
A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide 34
Safety and comfort of domestic bortezomib injection in real-life experience 34
Microfluidic chip technology applied to fine-needle aspiration cytology samples for IGH clonality assessment 34
Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status. 33
JURL-MK1 (c-kit(high)/CD30-/CD40-) and JURL-MK2 (c-kit(low)/CD30+/CD40+) cell lines: 'two-sided' model for investigating leukemic megakaryocytopoiesis. 33
Serum Pseudouridine In the Diagnosis of Acute Leukemias and As A Novel Prognostic Indicator In Acute Lymphoblastic-leukemia 33
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease 33
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. 32
A comprehensive genetic classification of adult Acute Lymphoblastic Leukemia (ALL): Analysis of the GIMEMA 0496 protocol. 32
The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial 32
Rituximab-containing risk-adapted treatment strategy in nodular lymphocyte predominant hodgkin lymphoma: 7-years follow-up 32
Cytotoxic T lymphocytes directed to the Preferentially Expressed Antigen of Melanoma (PRAME) target chronic myeloid leukemia. 32
Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib. 32
CIRCULATING MEGAKARYOCYTE-DERIVED CELLS DETECTED BY FLOW CYTOMETRY AS MARKER OF AGGRESSIVE NEOPLASM OF MEGAKARYOCYTIC LINEAGE IN ACUTE MEGAKARYOBLASTIC LEUKEMIA AND ALLIED MALIGNANCIES PRESENTING AS PRIMARY MYELOFIBROSIS 32
Totale 5.807
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.969
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.969
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201961 0 0 0 0 0 0 0 0 0 9 21 31
2019/20201.091 427 8 72 16 93 29 13 43 14 79 132 165
2020/20211.042 34 75 103 90 163 146 81 20 112 23 79 116
2021/20221.879 50 5 23 9 17 66 24 50 303 126 488 718
2022/20232.174 343 106 73 101 269 223 10 221 341 343 99 45
2023/2024984 58 194 201 68 91 120 19 179 27 27 0 0
Totale 10.071